MVM

Designed for rapid bone in-growth, regeneration and replacement, OSSIOfiber Intelligent Bone Regeneration Technology is a first-of-its-kind implant material stronger than cortical bone OSSIOfiber is engineered to provide the strength required for functional fixation and allows for full integration into the native anatomy without adverse biological response OSSIOfiber implants utilize existing reimbursement and surgical techniques

More than 10,000 OSSIOfiber implants have already been used in orthopedic surgeries since their commercial introduction in 2019

“We believe that OSSIO’s novel bio-integrative technology has the potential to transform the orthopedic fixation market,” said MVM’s Dr Stephen Reeders “We are excited to support the company’s mission to improve patient outcomes across a broad range of procedures ” Dr Reeders and his MVM colleague Dr Kevin Cheng join OSSIO’s board of directors as part of this financing

OSSIO is an orthopedic fixation company committed to transforming the orthopedic experience for patients, physicians and payors Founded in 2014, its vision is to provide the first credible replacement to metal implants in the multibillion-dollar global orthopedic fixation market with its OSSIOfiber Intelligent Bone Regeneration Technology OSSIO’s development headquarters is located in Caesarea, Israel, and its US headquarters is in Woburn, MA For more information on the company, visit www ossio io

Forward-looking statements contained herein are based on estimates and assumptions of OSSIO management and are believed to be reasonable, though they are inherently uncertain and difficult to predict

MVM has invested in high growth healthcare businesses since 1997 The firm has a broad, global investment outlook spanning medical technology, pharmaceuticals, diagnostics, digital health, and other sectors of healthcare

Clarivate acquires Patient Connect

Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced that […]

MVM invests in Vero Biotech

VERO Biotech Inc , a fast-growing commercial business dedicated to improving the lives of patients through innovative technologies, today announced the […]

MVM invests In Optinose

MVM invested $20 million in Optinose Optinose markets XHANCE, an innovative drug delivery system that delivers steroids high and deep […]

Paragon 28, Inc. announces pricing of Initial Public Offering

ENGLEWOOD, Colo , Oct 15, 2021 /PRNewswire/ — Paragon 28, Inc (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and […]

VERO Biotech Receives FDA Approval of its Third Generation Tankless Inhaled Nitric Oxide Delivery System

VERO Biotech Inc , a commercial-stage healthcare business dedicated to neonatal intensive care and the acute care hospital community, today announced […] BOSTON & LONDON — MVM Partners is pleased to announce the closing of its sixth healthcare fund, MVM VI, with […]

MVM invests in Neurolens

Neurolens, a company commercializing innovative solutions to optimize vision, today announced completion of a $67 million financing The financing was led by […]

MDxHealth acquires Oncotype DX GPS test

MDxHealth SA (NASDAQ/Euronext: MDXH) (“mdxhealth” or the “Company”), a commercial-stage precision diagnostics company, today announced it has entered into an […]

Nalu announces new CEO

Nalu Medical, Inc (“Nalu”), a private company focused on innovative and minimally invasive solutions for chronic neuropathic pain, announced today […]

MVM invests in Nalu Medical

CARLSBAD, Calif (PRWEB) February 17, 2022 Nalu Medical, Inc (“Nalu”), a private company focused on innovative and minimally invasive solutions for […]